Send
Print
Armin Kübelbeck
The deal will be done through a subsidiary of Merck, which will buy all of Acceleron's shares at $180 each. This brings the total purchase price to $11.5bn.
This deal is one of the largest acquisitions in Merck's history. Acceleron itself specializes in the development of drugs for respiratory diseases and blood diseases.
In particular, the company's portfolio includes an experimental drug for pulmonary arterial hypertension, a condition caused by high pressure in the blood vessels leading from the heart to the lungs. This condition leads to a reduction in the amount of oxygen in the blood. Competitors on the market are only able to slow down the treatment of the disease and relieve its symptoms, while Acceleron's drug could be the cure that stops the disease completely.
Talks between the companies were reported by The Wall Street Journal back on Monday. Acceleron's shares have since risen by around 10%.
source: wsj.com
This deal is one of the largest acquisitions in Merck's history. Acceleron itself specializes in the development of drugs for respiratory diseases and blood diseases.
In particular, the company's portfolio includes an experimental drug for pulmonary arterial hypertension, a condition caused by high pressure in the blood vessels leading from the heart to the lungs. This condition leads to a reduction in the amount of oxygen in the blood. Competitors on the market are only able to slow down the treatment of the disease and relieve its symptoms, while Acceleron's drug could be the cure that stops the disease completely.
Talks between the companies were reported by The Wall Street Journal back on Monday. Acceleron's shares have since risen by around 10%.
source: wsj.com
